Evaluating the application of next generation sequencing techniques in endoscopic retrograde cholangiopancreatography (ERCP) to improve diagnostic accuracy in patients with malignant biliary strictures
Editorial

Evaluating the application of next generation sequencing techniques in endoscopic retrograde cholangiopancreatography (ERCP) to improve diagnostic accuracy in patients with malignant biliary strictures

Tan To Cheung1,2

1Department of Surgery, The University of Hong Kong, Hong Kong, China; 2Department of Surgery, The University of Hong Kong Shenzhen Hospital, Shenzhen, China

Correspondence to: Dr. Tan To Cheung, FRCS, MS, MD. Clinical Associate Professor, Chief of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China. Email: tantocheung@hotmail.com.

Provenance and Peer Review: This article was commissioned by the editorial office, Hepatobiliary Surgery and Nutrition. The article did not undergo external peer review.

Comment on: Singhi AD, Nikiforova MN, Chennat J, et al. Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures. Gut 2020;69:52-61.


Submitted Aug 04, 2019. Accepted for publication Nov 12, 2019.

doi: 10.21037/hbsn.2019.11.18


Malignant biliary obstruction is a sinister condition that require radical treatment in order to provide the hope of a cure. Apart from complex surgery, the major clinical challenge remains the difficulty in making a conclusive diagnosis (1). There is a long list of differential diagnosis for obstruction of the bile duct including benign condition like primary sclerosing cholangitis, iatrogenic injury, infection and IgG 4 related conditions to malignant condition like carcinoma involving the whole course of bile duct, pancreatic carcinoma and adenocarcinoma in the periampullary regions (2-5).

In order to make a correct diagnosis, a very vigilant investigation from presenting history evaluation, physical examination, blood test, imaging and histological evaluation are needed. It requires a multidisciplinary team to perform all the task and to make the correct diagnosis.

One of the major pitfalls of current evaluation is that making a diagnosis depends heavily on biochemical testing (e.g., serum CEA and CA19-9 level), imaging patterns in ERCP and pathological evaluation by tissue obtained by ERCP. Unfortunately, the sensitivity of detection of cancer cell from ERCP brushing and biopsy has not been very sensitive in malignant condition ranging from lowest 8% to 67% as reported by various studies (6-10). The issue is even more complex in those scenarios where conditions maybe premalignant or radiologically malignant but the histopathology or cytology results turn out to be benign.

An easy to perform and yet accuracy test is needed in order to diagnose this condition.

Singhi et al. from the University of Pittsburgh had incorporated the use of next-generation sequencing (NGS) for gene testing to endoscopic retrograde cholangiopancreatography (ERCP) to enhance the diagnostic accuracy of biliary stricture condition (11). This was a prospectively designed study to take biopsy by ERCP and using the tissue obtained to be tested against a 28 gene panel. The result showed that the sensitivity and specificity of NGS for malignant strictures was 73% and 100%, respectively. This reflects an overall improvement in diagnosis when using conventional method by evaluating CA19-9 and tissue diagnosis with pathological examination. The conventional way for making a diagnosis gave a sensitivities of 76% and 48%, and specificities of 69% and 99%, respectively. The sensitivities of diagnosis will be increased from 83% to 99% when NGS was combined with histological examination.

The use of NSG was useful in patients with other benign condition like, primary sclerosing cholangitis (PSC). The sensitivity increased from 8% when using pathological evaluation to 83% when using NGS. Alteration in genomic could be identified by this new method and cholangiocarcinoma with specific gene characteristic can be detected. Target specific treatment could be given accordingly.

This study concluded that among the use of NGS together with conventional tissue diagnosis of biliary stricture increased the detection rate of malignant pathology. Among patients with primary sclerosing cholangitis, NGS was superior to serum CA19-9 and pathological evaluation in detecting at least high grade dysplasia.

The use of NGS for gene analysis had been shown to be useful and accurate option in other hepatobiliary and pancreatic condition. The same Pittsburgh group had performed another study for pancreatic cystic lesion, using clinical data of 626 pancreatic cystic fluid (PCF) specimens. Endoscopic ultrasound guided fine needle aspiration were performed in 595 patients. The specimen was sent for NGS Molecular analysis. The results were correlated with ancillary studies, EUS findings and follow-up (12).

Each pancreatic cystic pathology, the yield of diagnostic produced a different pattern. In Pancreatic cyst, KRAS/GNAS mutations were identified in 308 (49%) while alterations in TP53/PIK3CA/PTEN were present in 35 (6%) cases.

In patients with IPMN and MCNS, the KRAS/GNAS mutations detection rate were 100% and 30% respectively. The sensitivity for mucinous pancreatic cyst was 89% and 100% respectively. In comparison, KRAS/GNAS mutations by Sanger sequencing had a 65% sensitivity and 100% specificity.

In patients with advanced neoplasm, the sensitivity and specificity of combining KRAS/GNAS mutations and alterations in TP53/PIK3CA/PTEN was 89% sensitivity and 100% specificity by NGS.

Ductal dilatation, a mural nodule and malignant cytopathology had lower sensitivities (42%, 32% and 32%, respectively) and specificities (74%, 94% and 98%, respectively).

NGS of pancreatic cystic fluid analysis before operation for KRAS/GNAS mutations is highly sensitive for IPMNs and specific for mucinous PCs. The use of TP53/PIK3CA/PTEN alterations is a useful detection method for advanced pancreatic cancer before operation.

NGS had been proven to be an effective method in enhancing the accuracy in identifying a malignant condition in genetic level. Only a small quantity of sample was needed to provide a high sensitivity and specificity test result. This quality is extremely helpful in management of biliary stricture where only a small amount of tissue sample can be obtained.

Besides ERCP, the use of 18FDG PET CT scan may be useful to aid the diagnosis of malignant biliary stricture. Wang el at in a study of 66 patients demonstrated the role of PET scan preoperative evaluation (13). The maximum standardized uptake values (SUV) for malignant and benign lesions causing biliary obstruction were 8.2±4.4 and 4.0±5.0, respectively (P<0.05). This provided a good evidence of improving specificity, sensitivity and accuracy in evaluating benign stricture from malignant tumours. The sensitivity was 86.4%, the specificity was 73.7% and overall accuracy was 83.5% when 18F-FDG PET was used.

The conventional imaging produced a sensitivity, specificity and overall accuracy of 75.8%, 68.4% and 74.1% respectively. When 18F-FDG PET/CT is combined with conventional imaging, the sensitivity, specificity and overall accuracy changed to 95.5%, 57.9% and 87.1% respectively.

The use of PET CT together with NGS gene analysis may potentially increase the accuracy of detection of malignancy in patients with biliary strictures.

To conclude, this paper written by Singhi et al. is one of the largest series on the application of NGS to enhance the detection rate of malignancy in patients with biliary stricture. Apart from making a correct diagnosis, the additional information of genetic analysis provided patients with tailored made subsequent treatments that will potentially prolong the survival when precision medicine could be applied.


Acknowledgments

Funding: None.


Footnote

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/hbsn.2019.11.18). The author has no conflicts of interest to declare.

Ethical Statement: The author are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.


References

  1. Kapoor BS, Mauri G, Lorenz JM. Management of Biliary Strictures: State-of-the-Art Review. Radiology 2018;289:590-603. [Crossref] [PubMed]
  2. Aljahdli ES. Management of distal malignant biliary obstruction. Saudi J Gastroenterol 2018;24:71-2. [Crossref] [PubMed]
  3. Andaluz Garcia I, Gonzalez Partida I, Lucas Ramos J, et al. Painless jaundice as an initial presentation of lung adenocarcinoma. Rev Esp Enferm Dig 2018;110:520-1. [Crossref] [PubMed]
  4. Chang ZK, Kou ZP, Li SX, et al. To evaluate the correlation between the change of immune system function before and after the treatment of malignant obstructive type jaundice treated with biliary stent. Eur Rev Med Pharmacol Sci 2018;22:1638-44. [PubMed]
  5. Spapen J, Reekmans A, Berghmans B, et al. IgG4-related disease of the hepatobiliary tract: 2 case reports and review of the literature. Acta Gastroenterol Belg 2018;81:83-7. [PubMed]
  6. Foutch PG, Kerr DM, Harlan JR, et al. A prospective, controlled analysis of endoscopic cytotechniques for diagnosis of malignant biliary strictures. Am J Gastroenterol 1991;86:577-80. [PubMed]
  7. Farrell RJ, Jain AK, Brandwein SL, et al. The combination of stricture dilation, endoscopic needle aspiration, and biliary brushings significantly improves diagnostic yield from malignant bile duct strictures. Gastrointest Endosc 2001;54:587-94. [Crossref] [PubMed]
  8. Kurzawinski TR, Deery A, Dooley JS, et al. A prospective study of biliary cytology in 100 patients with bile duct strictures. Hepatology 1993;18:1399-403. [Crossref] [PubMed]
  9. de Bellis M, Fogel EL, Sherman S, et al. Influence of stricture dilation and repeat brushing on the cancer detection rate of brush cytology in the evaluation of malignant biliary obstruction. Gastrointest Endosc 2003;58:176-82. [Crossref] [PubMed]
  10. Stewart CJ, Mills PR, Carter R, et al. Brush cytology in the assessment of pancreatico-biliary strictures: a review of 406 cases. J Clin Pathol 2001;54:449-55. [Crossref] [PubMed]
  11. Singhi AD, Nikiforova MN, Chennat J, et al. Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures. Gut 2020;69:52-61. [Crossref] [PubMed]
  12. Singhi AD, McGrath K, Brand RE, et al. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia. Gut 2018;67:2131-41. [Crossref] [PubMed]
  13. Wang SB, Wu HB, Wang QS, et al. 18F-FDG PET/CT in differentiating malignant from benign origins of obstructive jaundice. Hepatobiliary Pancreat Dis Int 2015;14:516-22. [Crossref] [PubMed]
Cite this article as: Cheung TT. Evaluating the application of next generation sequencing techniques in endoscopic retrograde cholangiopancreatography (ERCP) to improve diagnostic accuracy in patients with malignant biliary strictures. Hepatobiliary Surg Nutr 2020;9(4):508-510. doi: 10.21037/hbsn.2019.11.18